Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
BPCL has demonstrated resilient financial performance, driven by strong refining performance, a growing gas business and strategic expansion plans. The revival of the Mozambique project and investment in the City Gas Distribution (CGD) business are positive developments. While the company's margin and pricing strategy will be crucial in navigating the volatile crude oil market, its significant capital expenditure...
*over or under performance to benchmark index IGL's dependence on higher-cost alternatives to offset lower APM allocations could impact margins. Although the guidance is bullish, with management aiming for an EBITDA margin of 78/scm in the long term, medium-term profitability risks persistespecially if the company is unable to implement price hikes. The Delhi EV 2.0 policy also remains an overhang, keeping the company out of favor. Therefore,...
At the operating level, EBITDA grew 30.3% YoY to Rs. 338cr in Q4FY25, while EBITDA margin increased a meagre 50bps to 11.6%. Reported PAT rose 34.5% YoY to Rs. 227cr in Q4FY25 from Rs. 168cr in Q4FY24, driven by robust top-line growth. KEI displayed robust financial performance in Q4FY25, marked by strong top-line and bottom-line growth. A favourable industry outlook, coupled with robust *over or under performance to benchmark index domestic and export demand, is expected to have a positive impact on the...
The company holds an order backlog of Rs.3,888cr, equivalent to 1x TTM revenue, ensuring near-term revenue visibility. However, the current NHAI ban and a lack of significant order inflows over the past nine months may adversely affect performance. We wait for further clarity on the subject...
*over or under performance to benchmark index Maruti Suzuki India Ltd. (MSIL) is an automobile manufacturer, in which Japanese car and motorcycle manufacturer Suzuki Motor Corporation owns 56.2%. MSIL is one of...
The EPC segment's revenue grew 46.7% YoY to Rs. 603cr due to effective execution of the RDSS order book. EBITDA rose 34.1% YoY to Rs. 1,025cr and EBITDA margin expanded 100bps to 14.7% owing to profits in the FMEG sector and strong margin in the EPC segment....
Sundram Fasteners Ltd (SFL), established in 1962 and headquartered in Chennai, India, is a flagship company of the TVS Group and a prominent player in the global automotive components industry. The company specializes in the manufacture of high-tensile fasteners(40% of revenue), powertrain components, and precision-engineered products, catering to both automotive and industrial sectors. With exports contributing 30% to its revenue, Sundram Fasteners has a strong presence in key international markets such as the U.S, Europe, and...
We cut FY26/FY27 EPS estimates by 0.7/3.5%, factoring in lower other income due to Rs4bn one time dividend paid in 3Q25. Operating parameters are showing an improvement led by 1) better demand conditions, supported by a higher number of wedding days in 1H26. 2) Stable store-level economics, aided by expansion into Tier-2 and Tier-3 cities. 3) BIS-related issues are expected to fully normalize over the next 912 months and 4) peaked out losses in FILA and expected scale up in Foot Locker and FILA from 2H26. Metro Brands Ltd (MBL)'s growth plans remain on track led by 1) Entry into...
Gujarat State Petronet (GSPL) reported a sharp decline in transmission volume to downward revision. Sequentially, implied tariff stood at Rs847/mscm, -3% QoQ. Lower volume and lower implied tariff resulted in EBITDA of Rs1.2bn, -35% QoQ (PLe & consensus Rs1.9bn). Higher interest cost resulted in even sharper...
incentives of Rs350mn and expect Rs510mn over FY26/27. The company expects MDF/plywood margin of 12%/7-8% in FY26. We had considered consolidated EBITDA margin of 11.8% with 1) steep increase in timber prices, 2) higher OEM vol in the MDF segment, 3) lower domestic volumes, and 4) lower realization with competition in MDF. Timber prices will continue to impact margins in coming quarters. The management has indicated moderation in...
Sun Pharma (SUNP) Q4FY25 EBIDTA (+11% YoY) was largely in line however moderate growth (9% YoY) in specialty sales after several quarters of strong double-digit growth was below our estimate. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...
